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A presentation of aids-related ophthalmic disease 
in a severely immunocompromised patient
By Sally Chetrit, oD
CLINICAL RESEARCH
Introduction
The human immunodeficiency virus (HIV) is a retrovirus causing progressive damage to the immune system by selectively 
attacking and destroying a specific type of  white blood cell, the CD4 T-
lymphocyte. The acquired immunodeficiency syndrome (AIDS) is known 
to be the final stage of  the HIV infection.1 A patient is classified as 
having AIDS when their CD4 T-lymphocyte count drops below 200 
cells per microlitre, or their CD4 T-lymphocyte percentage of  total 
lymphocytes is less than 14%.2 Prominent risk factors for contracting 
HIV include injection drug abuse and high risk sexual contact.3 As of  
December 2008, the Centers for Disease Control and Prevention esti-
mates that there are 1.1 million people living with HIV in the United 
States. This number is expected to grow as antiretroviral therapy pro-
longs the lives of  patients infected with HIV and inevitably increases 
the opportunity for transmission to others.4 In the last quarter century 
there has been a shift in demographics of  the AIDS epidemic: 25% 
of  HIV infections being diagnosed among women and the virus 
disproportionately affecting racial and ethnic minorities. Over half  of  
the new diagnoses are among African Americans.5,6
HIV retinopathy is the most common ocular manifestation of  
AIDS, affecting between 40% and 60% of  HIV-positive patients with 
CD4 T-lymphocyte count below 100 cells per microlitre.7 Clinically, 
this retinal microvasculopathy presents with cotton-wool spots and 
microaneurysms in the posterior pole. The presence of  HIV retino-
pathy is an important marker for patients with significantly compro-
mised immune status who are at risk for developing more severe and 
vision-threatening ocular opportunistic infections.7
Cytomegalovirus retinitis (CMVR) is the most common ocular  
opportunistic infection associated with AIDS, affecting approximately 
9% of  AIDS patients.7 There are two clinical forms of  CMVR. The 
fulminant form presents with confluent retinal necrosis and hemor-
rhaging in the posterior pole region. The indolent form of  CMVR 
presents as granular lesions in the peripheral retina, accompanied by 
little to no hemorrhaging. Treatment typically includes a course of  
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highly active anti-retroviral therapy 
(HAART), with concomitant  
administration of  anti-CMV  
specific agents.7
The following is the case of  a 
severely immunocompromised 
HIV positive patient who devel-
oped HIV retinopathy and  
subsequent CMVR. 
Case Report
A 40-year-old HIV-positive black 
male inpatient was referred to 
the Eye Clinic at the Woodhull 
Medical and Mental Health Center 
(Brooklyn, New York) for a com-
prehensive eye examination to rule 
out HIV-associated ophthalmic 
disease. 
The patient was diagnosed with 
HIV in July 2008. He was lost 
to follow-up until twelve weeks 
later, when he was admitted to the 
hospital with signs and symptoms 
of  acute esophagitis. It was at this 
time that the patient was referred 
to the Eye Clinic for his first 
evaluation. He presented without 
any ocular symptoms and a review 
of  systems revealed only a posi-
tive HIV status with concomitant 
esophagitis. 
At the time of  his admission, the 
patient presented with an elevated 
erythrocyte sedimentation rate, of  
82 mm/hr (reference 0-15 mm/hr), 
positive Cytomegalovirus immu-
noglobulin G titers, positive HIV 
antibody screening test (Western 
Blot), elevated quantity of  CMV 
DNA, with 2,733 copies/mL 
(reference < 200 copies/mL), and 
a CD4 T-lymphocyte count of  
7 cells/mL (reference 544-1894 
cells/mL). 
The patient had been initiated on 
HAART, and reported a compli-
ance rate of  greater than 95%. The 
patient’s therapy consisted of  the 
following agents: Kaletra® (Abbott 
Laboratories, North Chicago,  
Illinois), which is a co-formulation 
of  two protease inhibitors – lopi-
navir and ritonavir, and Truvada® 
(Gilead Sciences Inc, Foster City, 
California), which is a combination 
of  two nucleoside reverse tran-
scriptase inhibitors – emtricitabine 
and tenofovir. Both medications 
were administered orally, twice daily. 
Initial ocular examination  
revealed multiple cotton-wool 
spots in the posterior pole of  the 
left eye, without signs of  hemor-
rhage, or exudation (Figure 1). 
The right eye appeared to be clear 
of  microvascular anomalies (Figure 2). 
Visual acuities were measured to  
be 20/20-, right eye and left eye.  
The patient was diagnosed with 
HIV retinopathy of  left eye. No 
additional treatment was indicated, 
however, because of  the patient’s 
significantly low CD4 count, he 
was instructed to continue with 
current HAART regiment and to 
return to the Eye Clinic in one 
month for follow-up. Other than 
the cotton-wool spots detected 
Figure 1: Multiple cotton-wool spots at the posterior pole, left eye – initial visit.
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at this first visit, no evidence of  
CMVR was noted. As a result of  
his elevated CMV DNA count, the 
patient was labeled at high risk for 
developing the condition. 
At the one-month follow-up, a 
slight improvement in CD4 count 
was noted (10.4 cells/mL). Visual 
acuities were stable at 20/20-, right 
eye and left eye. Dilated fundus 
examination revealed two cotton-
wool spots at the posterior pole of  
the left eye. The right eye appeared 
stable from the previous visit, 
without signs of  retinopathy or 
retinitis. The diagnoses and man-
agement plan remained consistent; 
the patient was instructed to return 
for follow-up one month later.
At the repeat dilated fundus 
exam, one month later, visual 
acuities were stable, however one 
cotton wool spot was detected at 
the posterior pole of  the right eye, 
accompanied by a small hemor-
rhage. Two cotton wool spots 
were seen at the posterior pole of  
the left eye. The patient was then 
diagnosed with HIV retinopathy in 
both eyes, and deemed at high risk 
for CMVR. He was instructed to 
return to clinic no later than two 
weeks for follow-up.
The patient returned for follow-
up one month later. CD4 count at 
that visit was stable at 10 cells/mL. 
The patient continued to report 
100% compliance to the HAART 
treatment. Visual acuity of  the 
right eye was found to be reduced 
to 20/40-, left eye was relatively 
stable with an acuity of  20/20-. 
Dilated fundus examination of  the 
right eye revealed retinal hemor-
rhaging, necrosis, and edema along 
the inferior vascular arcade (Figure 3). 
Only one resolving cotton wool 
spot was seen in the left eye (Figure 4). 
The patient was diagnosed with 
CMVR of  the right eye, HIV 
retinopathy of  the left eye. The 
patient was immediately treated 
with Valgancyclovir 900 mg, orally, 
twice daily, for a period of  two 
weeks. He was instructed to return 
to clinic four days later. 
Subsequent follow-up exami-
nations revealed improvement 
in CMVR of  the right eye and 
HIV retinopathy of  the left eye. 
After the initiation of  anti-CMV 
therapy, the patient’s CMV DNA 
count (real-time polymerase chain 
reaction) had been reduced to 252 
copies/mL. The patient was dis-
charged from the hospital approxi-
mately two weeks after he began 
treatment with oral valgancyclovir. 
Once the two-week induction dose 
of  it was complete, the patient was 
prescribed a maintenance dose of  
oral valgancyclovir, 900 mg, daily, 
for an indefinite period of  time. 
At his most recent follow-up, 
approximately a month and a half  
after the patient’s diagnosis with 
CMVR, the CD4 count remained 
low at 9 cells/mL. Visual acuity 
was measured to be 20/25 in the 
right eye, 20/20 in the left eye. 
Fundus examination revealed a 
regressing retinitis of  the right eye, 
and no signs of  HIV retinopathy 
of  the left eye. As a result, the 
Figure 2: Posterior pole without signs of  
retinopathy, right eye – initial visit.
Figure 3: CMV Retinitis, right eye: 
Retinal hemorrhage, necrosis and edema – 
3 month follow-up.
Figure 4: Resolving cotton-wool spot, left 
eye – 3 month follow-up.
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patient was instructed to continue 
maintenance therapy with 900 mg 
of  oral valgancyclovir daily. The 
patient’s HAART regimen was 
modified at that visit, with an addi-
tional protease inhibitor, Invirase® 
(Roche Pharmaceuticals, Nutley, 
New Jersey) added to the therapy 
in an attempt to further reconsti-
tute the patient’s immune status. 
The patient was scheduled to be 
seen again, two weeks after his last 
visit to the Eye Clinic, but failed to 
keep his appointment.
 
(See Table 1 for a summary of  
the patient’s immune status and 
ophthalmic disease throughout the 
course of  his treatment.)
Discussion
HIV retinopathy is the most 
common ocular manifestation of  
AIDS, affecting between 40% and 
60% of  HIV-positive patients, 
typically with CD4 counts of  less 
than 50 cells/mL.7 Clinically, this 
retinal microvasculopathy presents 
with cotton-wool spots and micro-
aneurysms in the posterior pole.
Scattered dot and blot hemorrhages 
may be present, although cotton 
wool spots will rarely be associated 
with large amounts of  hemor-
rhaging.7 These microvascular 
changes resemble those of  non-
proliferative diabetic retinopathy, 
and are thought to be the result of  
retinal ischemia caused by reduced 
erythrocyte flow in HIV-positive 
patients.6,8,9,10,11 It is suspected that 
this microvasculopathy can cause 
progressive thinning of  the retinal 
nerve fiber layer12 and loss of  axons 
in the optic nerve,13 leading to a 
variety of  vision abnormalities,  
TABLE 1.
Correlation between the patient’s immune status and ophthalmic findings
Visit Date CD4+ 
Count
(cells/mL)
CMV viral 
load 
(copies/mL)
Ophthalmic fundus 
findings OD
Ophthalmic fundus 
findings OS
Diagnosis
1 10/2008 9 2,733 Clear Multiple cotton-wool 
spots at the posterior 
pole. No hemorrhages. 
No exudation.
HIV Retinopathy OS
2 11/2008 10.4 Not tested Clear Two cotton-wool spots 
at the posterior pole.
HIV Retinopathy OS
3 12/2008 Not tested Not tested One cotton-wool 
spot and one small 
hemorrhage at the 
posterior pole.
Two cotton-wool spots 
at posterior pole.
HIV Retinopathy OU
4 01/2009 10 Not tested Retinal hemorrhaging, 
necrosis and edema 
along inferior vascular 
arcade.
One resolving cotton-
wool spot at the 
posterior pole
CMVR OD
HIV Retinopathy OS
5 01/2009* 10 252 Retinal hemorrhage, 
necrosis and edema 
resolving.
Clear Resolving CMV 
Retinitis OD
6 03/2009 9 < 200 Retinal hemorrhage, 
necrosis and edema 
resolving.
Clear Resolving CMV 
Retinitis OD
*Following initiation of  anti-CMV therapy
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such as reduced colour vision, 
contrast sensitivity and visual 
field.14,15,16 Most patients with HIV 
retinopathy are asymptomatic,  
although occasionally a large 
cotton-wool spot located at the 
macula may cause a central scotoma. 
Rarely, this ischemic microvascu-
lopathy reaches the foveal region, 
resulting in macular edema or  
serous maculopathy, which leaves 
the patient symptomatic for 
blurred vision or abrupt vision 
loss.7 In most cases, treatment 
for HIV retinopathy is not indi-
cated. Focal laser photocoagula-
tion would be indicated in the 
rare cases of  macular edema. The 
presence of  ischemic microvascu-
lopathy is an important marker for 
patients with significantly com-
promised immune status who are 
at risk for developing more severe 
and vision-threatening ocular op-
portunistic infections. For patients 
with CD4 counts less than 50 
cells/mL, it is recommended to 
perform a dilated fundus ex-
amination at 3-month intervals to 
routinely screen for CMVR.7 In 
the case reported above, due to the 
elevated cytomegalovirus load, the 
patient was deemed to be at very 
high risk for developing CMVR 
and was therefore dilated on a 
monthly basis.
Cytomegalovirus is a double 
stranded DNA herpes virus that 
causes a necrotizing retinitis in  
immune deficient hosts.17,18 CMVR 
is the most common ocular oppor-
tunistic infection associated with 
AIDS, currently affecting approxi-
mately 9% of  AIDS patients.7,19 
Although the incidence of  CMVR 
and the risk of  associated retinal 
detachment has decreased since 
the advent of  HAART. It re-
mains the leading cause of  ocular 
morbidity among patients with 
AIDS.7,20 CMVR occurs almost 
exclusively in patients with CD4 
counts below 50 cells/mL.6,21 The 
average CD4 count at the time of  
diagnosis is 17 cells/mL.22 
There are two clinical forms of  
CMVR. The fulminant form pres-
ents with confluent retinal necrosis 
and hemorrhaging in the posterior 
pole region. Patients with this 
form will typically be symptomatic 
for reduced visual acuity and visual 
field. The indolent form of  CMVR 
presents as granular lesions in the 
peripheral retina, accompanied by 
frosted branch angiitis and little to 
no hemorrhaging.23 Patients with 
the above mentioned indolent 
form may commonly complain of  
floaters, or may be asymptomatic. 
In both cases, the retinal infec-
tion is “full-thickness” and begins 
peripherally and progresses cen-
trifugally along the retinal vascula-
ture.20 Although the patient in the 
above-mentioned case presented 
without symptoms, clinical signs 
of  hemorrhaging and necrosis at 
the posterior pole indicated the 
fulminant form of  this retinal 
infection. A low CD4 count makes 
inflammatory responses, such as 
vitritis, uncommon.24 Approxi-
mately 15% of  patients with active 
CMVR are asymptomatic, therefore 
it is recommended to perform  
dilated fundus exams at three-
month intervals when CD4 count 
is less than 50 cells/mL.25
Treatment of  CMVR is not only 
based on the patient’s immune 
status, but also takes into account 
the location of  the active retini-
tis.7 Treatment typically includes 
initiating or modifying, a course 
of  HAART in an effort to re-
constitute the immune system. 
Since immune reconstitution can 
be delayed after the initiation of  
HAART, concomitant use of  anti-
CMV agents is indicated in  
patients with posterior CMVR that 
is imminently vision threatening.7 
The current standard for the 
treatment of  CMV retinitis is sys-
temic gancyclovir or its prodrug, 
valgancyclovir. Systemic gancyclo-
vir is administered intravenously 
for a period of  two to three weeks, 
at a dose of  5 mg/kg, twice daily. 
This induction therapy is followed 
by maintenance with oral gancyclo-
vir, at a dose of  30 mg daily.7 Sys-
temic valgancyclovir is considered 
to be equivalent to gancyclovir as 
initial therapy for CMVR, with an 
added advantage of  being admin-
istered orally for both induction 
and maintenance therapy.6,26,27 The 
recommended oral dose for induc-
tion therapy is 900 mg, twice daily, 
for a period of  two to three weeks. 
This is followed by oral mainte-
nance therapy of  900 mg, daily.  
All above-mentioned doses  
assume normal renal function; as 
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creatinine clearance reduces, the 
induction and maintenance doses 
are also reduced. Common second-
ary effects of  the above-mentioned 
medications include blood dyscrasia 
(neutropenia, thrombocytopenia, 
anemia) and nephrotoxicity.28 
Periodic monitoring of  renal func-
tion and blood counts are recom-
mended for all patients initiated on 
these therapies. 
Other alterative treatments for 
CMVR include foscarnet, cido-
fovir and fomvirsen. Foscarnet 
is administered intravenously for 
both induction and maintenance 
therapy. It has been proven to have 
equal effectiveness as gancyclovir, 
only with more intolerable side 
effects.29 Secondary effects of  fos-
carnet include seizures due to elec-
trolyte imbalance, neutropenia and 
nephrotixicity.30,31 It has also been 
reported that 37% of  patients on 
foscarnet develop resistance to 
the medication within a treatment 
period of  nine months.32 Cidofovir 
administered intravenously, can be 
combined with oral gancyclovir 
to provide a synergistic effect that 
prolongs the patient’s relapse-free 
intervals.33 Disadvantages of  using 
cidofovir include secondary effects 
of  proteinuria, peripheral neuro-
pathy, ocular hypotony, and ante-
rior uveitis.34,35 Ocular hypotony 
can be treated with a combination 
of  topical ibopamine and dexa-
methasone. Anterior uveitis can be 
treated with topical corticosteroid 
therapy.36,37,38 As a second line of  
treatment, fomvirsen is adminis-
tered intravitreally for both induc-
tion and maintenance therapy. Its 
use has been limited to cases of  
CMVR that are refractory to more 
conventional therapy; patients who 
are intolerant to the previously 
mentioned therapies; or in the 
presence of  any contraindications 
to the alternative medications. The 
disadvantages of  treating with 
fomvirsen lie within the secondary 
effects associated with intravitreal 
injections, they include: vitreous 
hemorrhage, retinal detachment 
and endophthalmitis.7
The gancyclovir intravitreal 
implant may be used for induction 
and maintenance therapy and is 
most indicated in cases of  macula-
threatening CMVR. The implant 
is inserted through the pars plana 
and releases high levels of  the 
drug directly into the vitreous hu-
mor for a period of  approximately 
eight months.6 Advantages of  the 
gancyclovir implant include local 
drug delivery at elevated concen-
trations providing the highest de-
gree of  viral suppression, longest 
relapse-free intervals, and lack of  
systemic toxicity.7,20 The disadvan-
tages include potential complica-
tions of  implant insertion,39,40 such 
as vitreous hemorrhage, endo-
phthalmitis, retinal detachment, 
lack of  protection against systemic 
CMV, or CMVR in the contralat-
eral eye.7 In the case mentioned 
above, the infection appeared to 
be sparing the macula and, as a 
result, the risks of  treating with a 
gancyclovir implant out-weighed 
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the benefits. A more conservative 
approach to treat with oral gancy-
clovir was therefore elected.
The use of  oral gancyclovir as a 
prophylactic treatment against ocu-
lar or systemic CMV is quite con-
troversial. Numerous studies reveal 
non-concordant conclusions re-
garding the efficacy of  prophylactic 
gancyclovir. Other disadvantages 
of  prescribing gancyclovir prophy-
lactically include toxicity, cost, and 
the development of  resistances.7,41,42 
Although the patient in this case 
presented with a low CD4 count, 
presence of  HIV retinopathy and 
elevated CMV viral load, prophy-
lactic treatment was not considered 
for the above-mentioned reasons.
It has been suggested that pa-
tients treated with HAART who 
sustain an elevated CD4 count on 
two consecutive measurements tak-
en three months apart, and whose 
CMVR remains regressed and 
quiescent on maintenance therapy 
for more than 4 months, may safely 
discontinue anti-CMV therapy with 
close observation for reactivation.43 
More specifically, the criteria for 
selecting appropriate candidates for 
the discontinuation of  maintenance 
therapy includes a sustained CD4 
count greater than 100 cells/mL for 
at least three months, completely 
quiescent retinitis, prolonged 
relapse-free intervals, prolonged 
HAART regimen (a minimum of  
18 months), and reduced HIV and 
CMV viral load.7
 
Conclusion
This case shows the rapid progres-
sion of  HIV-related retinal disease 
with significantly reduced immune 
status. Although the incidence of  
CMVR has decreased since the ad-
vent of  HAART, it still remains the 
leading cause of  ocular morbidity 
associated with AIDS. It is strongly 
recommended that eye care pro-
fessionals perform routine dilated 
fundus examinations at an interval 
of  3 months in all HIV-positive 
patients with HIV retinopathy and/
or a CD4 count of  less than 50 
cells/mL.
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